FDA Panel Backs BPC-157 and TB-500 for Compounding
Tom Gallagher · Senior Editor
August 30, 2026 · 1 min read
The vote, plainly
An FDA advisory panel voted in July 2026 to recommend BPC-157 and TB-500 for the Section 503A bulks list. BPC-157 passed 8 to 6. TB-500 passed 8 to 6. Four other peptides, KPV, MOTS c, Epitalon, and Semax, also got favorable votes, per FDA meeting records and PharmExec.
Read the vote correctly. It is a recommendation, not a rule. Neither peptide gained FDA approval as a drug. Both remain unapproved for human use, and both are still sold as research compounds. HHS must act before either substance can legally move onto a compounding list. The FDA itself opposed the nominations going in, per its own briefing document. Watch this space, not your shelf.
Common questions
Are BPC-157 and TB-500 FDA approved now? No. A panel recommended them for a compounding list. That is not drug approval.
Does this vote change anything today? No. HHS has to act first. Nothing about legal status has changed yet.
Why did the FDA oppose the nominations? The agency's own briefing flagged limited human safety data before the vote.
This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.
FAQ
Are BPC-157 and TB-500 FDA approved now?
No. A panel recommended them for a compounding list. That is not drug approval.
Does this vote change anything today?
No. HHS has to act first. Nothing about legal status has changed yet.
Why did the FDA oppose the nominations?
The agency's own briefing flagged limited human safety data before the vote.
Ready to explore peptides?
Browse every compound profile or work out your dose with the reconstitution calculator.